Skip to main content
. 2023 Feb 13;19(1):2171233. doi: 10.1080/21645515.2023.2171233

Figure 2.

Figure 2.

Recombinant M. Smegmatis-based vaccine could induce the activation and maturation of antigen-presenting cells. (a) the expression level of co-stimulatory molecules on Raw264.7 and DC 2.4 cells after being infected with ZWY2-S or ZWY2-N bacteria. The red peak represents the medium control group, and the blue one represents the recombinant M. smegmatis treated group. (b) the mRNA levels of IFN-β, TNF-α, IL-6, and IL-1β in Raw264.7 and DC2.4 cells after being infected with ZWY2-S or ZWY2-N. These data were expressed as the mean ± SEM from two individual trials (*: P < .05; **: P < .01; ***: P < .001).